[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY33802A - Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja - Google Patents

Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja

Info

Publication number
UY33802A
UY33802A UY0001033802A UY33802A UY33802A UY 33802 A UY33802 A UY 33802A UY 0001033802 A UY0001033802 A UY 0001033802A UY 33802 A UY33802 A UY 33802A UY 33802 A UY33802 A UY 33802A
Authority
UY
Uruguay
Prior art keywords
immunogenic compositions
ionic strength
low ionic
antigen related
antigen
Prior art date
Application number
UY0001033802A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Stephane Andre Georges Godart
Laanan Amina
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of UY33802A publication Critical patent/UY33802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones inmunógenas que comprenden un antígeno relacionado con M72, en las que la conductividad de la composición es de 13 mS/cm o menor, o la concentración de sales de la composición es de 130 mM o menor, y su uso en medicina.
UY0001033802A 2010-12-14 2011-12-14 Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja UY33802A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14

Publications (1)

Publication Number Publication Date
UY33802A true UY33802A (es) 2012-07-31

Family

ID=45346501

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033802A UY33802A (es) 2010-12-14 2011-12-14 Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja

Country Status (32)

Country Link
US (5) US9352030B2 (es)
EP (4) EP3593813A1 (es)
JP (2) JP5951633B2 (es)
KR (3) KR20140029376A (es)
CN (4) CN103249431B (es)
AR (1) AR084285A1 (es)
AU (2) AU2011343367B2 (es)
BR (2) BR112013014599A2 (es)
CA (2) CA2819298A1 (es)
CO (2) CO6751287A2 (es)
CY (1) CY1122187T1 (es)
DK (3) DK2651436T3 (es)
EA (2) EA027504B1 (es)
ES (3) ES2748651T3 (es)
HR (3) HRP20160362T1 (es)
HU (3) HUE045766T2 (es)
IL (2) IL226450A0 (es)
LT (1) LT3023106T (es)
ME (1) ME02380B (es)
MX (2) MX344280B (es)
MY (1) MY161412A (es)
PL (3) PL2651437T3 (es)
PT (2) PT2651436E (es)
RS (1) RS54687B1 (es)
SG (2) SG190731A1 (es)
SI (3) SI2651436T1 (es)
SM (1) SMT201600118B (es)
TW (1) TW201305192A (es)
UA (2) UA110806C2 (es)
UY (1) UY33802A (es)
WO (2) WO2012080369A1 (es)
ZA (2) ZA201304015B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524570T3 (es) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedimiento de prevención o tratamiento de infección por M. tuberculosis
RS54687B1 (en) * 2010-12-14 2016-08-31 Glaxosmithkline Biologicals S.A. COMPOSITION OF MYCOBACTERIAL ANTIGENS
WO2012093137A1 (en) 2011-01-04 2012-07-12 Archivel Farma, Sl Liposome formulation suitable for treating or preventing tuberculosis
DK2802345T3 (en) 2012-01-12 2018-04-30 Archivel Farma Sl MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
ES2759260T3 (es) 2014-04-23 2020-05-08 Juno Therapeutics Inc Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE20190086A1 (en) 2017-05-30 2019-12-25 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
US20210292395A1 (en) 2018-07-31 2021-09-23 Glaxosmithkline Biologicals Sa Antigen purification method
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3092525A1 (en) 2019-09-09 2021-03-09 Glaxosmithkline Biologicals S.A. Immunotherapeutic compositions
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
CN115485057A (zh) 2020-05-05 2022-12-16 葛兰素史克生物有限公司 微流体混合装置和使用方法
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
MX2023006769A (es) 2020-12-09 2023-08-18 Glaxosmithkline Biologicals Sa Modificacion de saponinas.
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
HU225979B1 (en) 1995-09-01 2008-02-28 Corixa Corp Compounds and methods for immunotherapy and diagnosis of tuberculosis
DE69636075D1 (de) 1995-09-01 2006-06-01 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
NZ500028A (en) * 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
AU746163B2 (en) * 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CA2386841A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE526994T1 (de) 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
SK288007B6 (sk) 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
ES2524570T3 (es) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2008140478A2 (en) * 2006-11-01 2008-11-20 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
SI2148697T1 (sl) 2007-05-24 2013-01-31 Glaxosmithkline Biologicals S.A. Liofilizirani sestavek, ki vsebuje CpG in WT-1
NZ709704A (en) * 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
RS54687B1 (en) 2010-12-14 2016-08-31 Glaxosmithkline Biologicals S.A. COMPOSITION OF MYCOBACTERIAL ANTIGENS
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
EP2651437B1 (en) 2016-02-10
JP5951633B2 (ja) 2016-07-13
IL226448A (en) 2017-09-28
UA110806C2 (uk) 2016-02-25
ZA201304015B (en) 2018-12-19
SI3023106T1 (sl) 2019-11-29
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
HRP20191843T1 (hr) 2019-12-27
CN106822883A (zh) 2017-06-13
KR101951894B1 (ko) 2019-02-26
PT3023106T (pt) 2019-11-04
SI2651437T1 (sl) 2016-05-31
CO6751288A2 (es) 2013-09-16
CN103260642B (zh) 2018-03-16
SMT201600118B (it) 2016-07-01
US20160220656A1 (en) 2016-08-04
JP2014505036A (ja) 2014-02-27
EP3023106A1 (en) 2016-05-25
MX2013006819A (es) 2013-08-26
KR20140029376A (ko) 2014-03-10
PL2651437T3 (pl) 2016-07-29
DK2651436T3 (da) 2016-06-20
EP3593813A1 (en) 2020-01-15
ES2574403T3 (es) 2016-06-17
CN106822882A (zh) 2017-06-13
PL2651436T3 (pl) 2016-10-31
US20190183998A1 (en) 2019-06-20
US20130280289A1 (en) 2013-10-24
WO2012080370A1 (en) 2012-06-21
CO6751287A2 (es) 2013-09-16
EA027504B1 (ru) 2017-08-31
PL3023106T3 (pl) 2019-12-31
JP2013545783A (ja) 2013-12-26
AU2011343367B2 (en) 2015-05-21
MX2013006818A (es) 2013-08-26
MX344706B (es) 2017-01-03
US9730992B2 (en) 2017-08-15
JP5951634B2 (ja) 2016-07-13
BR112013014599A2 (pt) 2016-09-27
DK3023106T3 (da) 2019-09-30
HRP20160606T1 (hr) 2016-07-01
US9352030B2 (en) 2016-05-31
TW201305192A (zh) 2013-02-01
HUE027932T2 (en) 2016-11-28
EP2651436A1 (en) 2013-10-23
RS54687B1 (en) 2016-08-31
CN103249431B (zh) 2016-11-02
EA201390630A1 (ru) 2013-12-30
CN103260642A (zh) 2013-08-21
ES2748651T3 (es) 2020-03-17
CA2819297A1 (en) 2012-06-21
AR084285A1 (es) 2013-05-08
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
BR112013014598A2 (pt) 2017-09-19
US20130287809A1 (en) 2013-10-31
LT3023106T (lt) 2019-10-25
CY1122187T1 (el) 2020-11-25
MY161412A (en) 2017-04-14
UA110118C2 (uk) 2015-11-25
AU2011343367A1 (en) 2013-07-11
KR20130124525A (ko) 2013-11-14
MX344280B (es) 2016-12-09
ES2567190T3 (es) 2016-04-20
EP2651437A1 (en) 2013-10-23
CN103249431A (zh) 2013-08-14
AU2011343368B2 (en) 2015-08-20
SG190937A1 (en) 2013-07-31
IL226450A0 (en) 2013-07-31
PT2651436E (pt) 2016-06-08
ZA201304014B (en) 2017-04-26
EP3023106B1 (en) 2019-07-31
WO2012080369A1 (en) 2012-06-21
EA027920B1 (ru) 2017-09-29
SI2651436T1 (sl) 2016-07-29
AU2011343368C1 (en) 2015-12-24
EP2651436B1 (en) 2016-03-30
AU2011343368A1 (en) 2013-07-11
KR20190022897A (ko) 2019-03-06
DK2651437T3 (en) 2016-05-02
CA2819298A1 (en) 2012-06-21
EA201390631A1 (ru) 2014-11-28
US20180071378A1 (en) 2018-03-15
SG190731A1 (en) 2013-07-31
HUE028452T2 (en) 2016-12-28
IL226448A0 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
UY33802A (es) Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja
ECSP11011297A (es) Proteinas ligadoras il-17
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
CL2014002564A1 (es) Composiciones para tratamiento de agua que comprende un coagulante que contiene aluminio y un polisacarido no derivado natural, en donde la relacion entre el polisacarido y el coagulante es entre 1:10 hasta 1:100; y métodos de uso.
CR20120578A (es) Formulaciones de insulina de acción prolongada
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
BR112015006426A2 (pt) composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos
BR112015000520A2 (pt) agente de espessamento estável com lipase
EA201190286A1 (ru) Адъювантные композиции, содержащие неионный агент, обеспечивающий изотоничность
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA201290789A1 (ru) Термогелеобразующие композиции анестетиков
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CO6592098A2 (es) Formulacion estable de mia/cd-rap
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BR112015028824A2 (pt) composição de tensoativo concentrada
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
FR2987269B1 (fr) Formulation gelifiante a base de gluconate de calcium
AR093717A1 (es) Composiciones y metodos para el tratamiento de la caries dental
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
IT1394921B1 (it) Uso di composti come principi attivi per migliorare l'azione di riparazione cellulare dell'epidermide umana, e composizioni farmaceutiche e cosmetiche che li contengono
AR116040A2 (es) Sal tosilato para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3h-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida del ácido ciclopropancarboxílico
CR20140526A (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20130805